How to buy Biocept stock (BIOC)

Biocept is a diagnostics & research business based in the US. Biocept shares (BIOC) are listed on the NASDAQ and all prices are listed in US Dollars. Biocept employs 50 staff and has a trailing 12-month revenue of around $1.4 million.

Our top picks for where to buy Biocept stock

Buy Biocept stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Biocept stock price (NASDAQ: BIOC)

Use our graph to track the performance of BIOC stocks over time.

Biocept shares at a glance

• Key figures

Information last updated 2024-02-18.

52-week range	$0.03 - $0.09
50-day moving average more info button	$0.95
200-day moving average more info button	$5.33
Wall St. target price	$4.00
PE ratio more info button	N/A
Dividend yield more info button	$0 (0%)
Earnings per share (TTM) more info button	$-48.17

Is it a good time to buy Biocept stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Biocept financials

Revenue TTM	$1.4 million
Gross profit TTM	$-2,582,000
Return on assets TTM	-51.65%
Return on equity TTM	-186.94%
Profit margin	0%
Book value	$0.12
Market Capitalization more info button	$1.1 million

TTM: trailing 12 months

Biocept share dividends

We're not expecting Biocept to pay a dividend over the next 12 months.

Have Biocept's shares ever split?

Biocept's shares were split on a 1:30 basis on 16 May 2023 . So if you had owned 30 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Biocept shares – just the quantity. However, indirectly, the new 2900% higher share price could have impacted the market appetite for Biocept shares which in turn could have impacted Biocept's share price.

Biocept share price volatility

Over the last 12 months, Biocept's shares have ranged in value from as little as $0.0251 up to $0.0887. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Biocept's is 0.595. This would suggest that Biocept's shares are less volatile than average (for this exchange).

Biocept overview

Biocept, Inc. , a molecular oncology diagnostics company, develops and commercializes proprietary clinical diagnostic laboratory assays designed to identify rare tumor cells and cell-free tumor DNA from blood and cerebrospinal fluid, or CSF in the United States. Its cancer assays provide information to healthcare providers to identify oncogenic alterations that qualify a subset of cancer patients for targeted therapy at diagnosis, progression, and monitoring to identify resistance mechanisms. The company offers assays for solid tumor indications, such as breast cancer, non-small cell lung cancer (NSCLC), gastric cancer, colorectal cancer, prostate cancer, pancreaticobiliary cancer, and ovarian cancer. It also provides cerebrospinal fluid tumor cell and ctDNA and ctRNA testing services to medical oncologists, neuro-oncologists, surgical oncologists, radiation oncologists, urologists, pulmonologists, pathologists, and other physicians; and clinical trial and research services to pharmaceutical companies, biopharmaceutical companies and clinical research organizations. The company has a collaboration with CLEARED4 to develop a system for tracking and managing COVID-19 testing requirements and test results for its customers; and with Protean BioDiagnostics, Inc. to research the ability of its Target Selector molecular assay to determine EGFR status in NSCLC patients.

Frequently asked questions

null
What percentage of Biocept is owned by insiders or institutions?
Currently 9.209% of Biocept shares are held by insiders and 1.982% by institutions. How many people work for Biocept?
Latest data suggests 50 work at Biocept. When does the fiscal year end for Biocept?
Biocept's fiscal year ends in December. Where is Biocept based?
Biocept's address is: 9955 Mesa Rim Road, San Diego, CA, United States, 92121 What is Biocept's ISIN number?
Biocept's international securities identification number is: US09072V5012 What is Biocept's CUSIP number?
Biocept's Committee on Uniform Securities Identification Procedures number is: 09072V402